296 related articles for article (PubMed ID: 27831500)
1. LPA Gene, Ethnicity, and Cardiovascular Events.
Lee SR; Prasad A; Choi YS; Xing C; Clopton P; Witztum JL; Tsimikas S
Circulation; 2017 Jan; 135(3):251-263. PubMed ID: 27831500
[TBL] [Abstract][Full Text] [Related]
2. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.
Tsimikas S; Clopton P; Brilakis ES; Marcovina SM; Khera A; Miller ER; de Lemos JA; Witztum JL
Circulation; 2009 Apr; 119(13):1711-9. PubMed ID: 19307470
[TBL] [Abstract][Full Text] [Related]
3. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
[TBL] [Abstract][Full Text] [Related]
4. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
5. Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.
Kamstrup PR; Hung MY; Witztum JL; Tsimikas S; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1570-1578. PubMed ID: 28572160
[TBL] [Abstract][Full Text] [Related]
6. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.
Karwatowska-Prokopczuk E; Clouet-Foraison N; Xia S; Viney NJ; Witztum JL; Marcovina SM; Tsimikas S
Atherosclerosis; 2021 May; 324():102-108. PubMed ID: 33872986
[TBL] [Abstract][Full Text] [Related]
8. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
9. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
Tsimikas S; Duff GW; Berger PB; Rogus J; Huttner K; Clopton P; Brilakis E; Kornman KS; Witztum JL
J Am Coll Cardiol; 2014 May; 63(17):1724-34. PubMed ID: 24530664
[TBL] [Abstract][Full Text] [Related]
10. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
[TBL] [Abstract][Full Text] [Related]
12. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
14. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.
Capoulade R; Chan KL; Yeang C; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Mahmut A; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
J Am Coll Cardiol; 2015 Sep; 66(11):1236-1246. PubMed ID: 26361154
[TBL] [Abstract][Full Text] [Related]
15. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study.
Clarke R; Hammami I; Sherliker P; Valdes-Marquez E; Watkins H; Hill M; Yang X; Tsimikas S; Hopewell JC;
Atherosclerosis; 2022 Aug; 354():15-22. PubMed ID: 35803063
[TBL] [Abstract][Full Text] [Related]
18. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
[TBL] [Abstract][Full Text] [Related]
19. Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification.
Pechlivanis S; Mahabadi AA; Hoffmann P; Nöthen MM; Broecker-Preuss M; Erbel R; Moebus S; Stang A; Jöckel KH
BMC Med Genet; 2020 Mar; 21(1):62. PubMed ID: 32220223
[TBL] [Abstract][Full Text] [Related]
20. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
